July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A retrospective surveillance study of critical care units at a tertiary care hospital found high CAUTI/UTI and CLABSI rates, with CLABSI rates increasing 2.64-fold during the COVID-19 era.
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
June 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved cefepime and zidebactam (Zaynich, Wockhardt), a novel intravenous antibiotic, for adults with complicated urinary tract infections, including pyelonephritis, caused by susceptible...
In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...
A phase 3 trial evaluates whether first-line disitamab vedotin combined with toripalimab could improve outcomes compared with platinum-based chemotherapy in patients with previously untreated...
On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
A multicenter randomized trial has demonstrated that the NeuroSAFE technique significantly improves erectile function and accelerates early urinary continence recovery following robot-assisted radical...
